KalVista Q1: EKTERLY approved in US/UK; 460 patient start forms; positive CHMP opinion

KalVista Pharmaceuticals, Inc.

2026-Q1 EPS reported -$1.12 revenue$1,400,000

EKTERLY (sebetralstat) FDA approved July 7, 2025; UK MHRA authorized same month; positive CHMP opinion; EU decision expected Oct 2025.
Received 460 patient start forms through August 29, 2025 (nearly 5% of US HAE patients).
Net product revenue $1.4M from US sales; R&D expenses $15.2M (down 43% YoY); SG&A $44.7M (up 154% YoY due to commercialization).
Cash and marketable securities $191.5M as of July 31, 2025; runway into 2027.
Orphan designation maintained in EU; 10 years market exclusivity; one of only two HAE medicines with orphan status.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.